Pairing the endless possibilities of space exploration with the limitless opportunities of education, Texas Instruments (TI) (NASDAQ: TXN) and NASA are partnering to show students how science, technology, engineering and math (STEM) make feats like space exploration possible with mISSion imaginaTIon. The partnership and its programs aim to spur the imaginations of the next generation of scientists, engineers, explorers and innovators who are in today’s math and science classrooms.
Combining expertise, TI Education Technology and NASA have developed programs that promote STEM-focused lessons for students and teachers in middle and high school. Launching today, the mISSion imaginaTIon online quiz allows participants to see if they have what it takes for a year-long mission aboard the International Space Station. After discovering how ready they are to live in space, students can then put their STEM skills to the test with the mISSion imaginaTIon design challenge, which asks students to devise solutions to four space-related challenges.
“Imagination is the fuel that feeds progress and innovation,” said Peter Balyta, Ph.D., (@pbalyta), president of TI Education Technology. “Alongside NASA, we are excited to unleash student creativity as students explore how science, technology, engineering and math can solve future problems on earth, in space and beyond.”
To view the multimedia release go to:
http://www.multivu.com/players/English/7418651-ti-nasa-mission-imagination/
For the first time a YSL skincare product joins the collection at a science museum. Glycobiology, the science of glycans applied to the skin and cosmetics pioneered by YSL Beauté with FOREVER YOUTH LIBERATOR SERUM, is now part of the Berlin Museum‘s newly inaugurated permanent exhibition dedicated to the central role played by glycans in the realm of life.
After being closed for renovations for three years, the Berlin-based Sugar Museum has reopened as part of the Deutsches Technikmuseum with an expanded exhibition about sugars: “Sugars and Beyond! Food – Matter – Energy”, from November 26, 2015. In addition to the traditional focus of the former Sugar Museum, which concentrated on the production, use and social history of cane and beet sugars, the newly opened exhibition sheds light on the topic of sugar from entirely new perspectives.
To view the multimedia release go to:
http://www.multivu.com/players/uk/7709551-ysl-beaute-forever-youth-liberator-serum/
For the first time a YSL skincare product joins the collection at a science museum. Glycobiology, the science of glycans applied to the skin and cosmetics pioneered by YSL Beauté with FOREVER YOUTH LIBERATOR SERUM, is now part of the Berlin Museum‘s newly inaugurated permanent exhibition dedicated to the central role played by glycans in the realm of life.
After being closed for renovations for three years, the Berlin-based Sugar Museum has reopened as part of the Deutsches Technikmuseum with an expanded exhibition about sugars: “Sugars and Beyond! Food – Matter – Energy”, from November 26, 2015. In addition to the traditional focus of the former Sugar Museum, which concentrated on the production, use and social history of cane and beet sugars, the newly opened exhibition sheds light on the topic of sugar from entirely new perspectives.
To view the multimedia release go to:
http://www.multivu.com/players/uk/7709551-ysl-beaute-forever-youth-liberator-serum/
Autism Speaks – the world’s leading autism science and advocacy organization – today joined the Ad Council and BBDO New York, the long-time volunteer agency for Autism Speaks, to announce the launch of a new series of public service advertisements (PSAs) designed to help parents recognize the early signs of autism and take immediate action. For the first time in the campaign’s history, the new PSAs feature an imaginative world, created using 3D and stop-motion animation, inspired by stories of real children with autism and told from the perspective of a child with autism. The PSAs are an extension of the award-winning “Learn the Signs” campaign, created by BBDO, which has helped significantly increase the percentage of parents who recognize the early warning signs of autism.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7674151-ad-council-autism-speaks-psa-s-2015/
Leveraging advanced skincare science inspired by the Nobel Prize-winning discovery of Aquaporins, the Artistry Hydra-V™ collection presents a new level of skincare targeting deep hydration. This comprehensive line provides up to 24-hour hydration for skin that feels soft, smooth and supple.
Whatever level of hydration skin needs, the Artistry Hydra-V™ line answers with a range of formulas that can be customized to skin type, season and climate. “Artistry Hydra-V™ products are for the younger consumer who is not yet concerned with the signs of aging but instead want skincare products to give her a beautiful, healthy complexion. This advancement in skincare technology epitomizes the Artistry® Forward Beauty platform and meets the balanced hydration needs of women younger than 35,” says Jackie Nickel, Chief Marketing Officer for the Americas Region. “It’s our first collection to focus on deep hydration for all skin types.”
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7488157-amway-artistry-hydra-v/
Researchers presenting at ASTRO 2015, the premier radiation oncology scientific event in the world, unveiled new data this week that could fundamentally change the way that early stage breast cancer is treated.
Results from a landmark prospective, randomized, multicenter phase III study conducted in Europe demonstrated that APBI brachytherapy leads to equivalent overall survival and local cancer control rates as compared to WBI after breast conserving surgery for selected patients with early stage breast cancers. These data were presented during the ASTRO official press conference and published in The Lancet, a leading high-impact global peer-reviewed medical journal.
“We have been confidently offering APBI brachytherapy to selected women for years based on numerous phase II, single site and large registry studies that have confirmed the clinical utility of site-specific radiation delivered in a condensed timeframe,” said Frank A. Vicini, M.D., radiation oncologist, 21st Century Oncology, Royal Oak, Mich. and contributing author to the 2009 and 2013 ASTRO and ABS APBI guidelines. “The results from this landmark, multicenter, prospective randomized clinical study are the first to offer the critical level one evidence necessary to drive the fundamental changes in breast conserving cancer treatment that patients and healthcare professionals have been demanding for years.”
To view the multimedia release go to:
http://www.multivu.com/players/uk/7661231-new-apbi-brachytherapy-data-at-astro-2015/
Researchers presenting at ASTRO 2015, the premier radiation oncology scientific event in the world, unveiled new data this week that could fundamentally change the way that early stage breast cancer is treated.
Results from a landmark prospective, randomized, multicenter phase III study conducted in Europe demonstrated that APBI brachytherapy leads to equivalent overall survival and local cancer control rates as compared to WBI after breast conserving surgery for selected patients with early stage breast cancers. These data were presented during the ASTRO official press conference and published in The Lancet, a leading high-impact global peer-reviewed medical journal.
“We have been confidently offering APBI brachytherapy to selected women for years based on numerous phase II, single site and large registry studies that have confirmed the clinical utility of site-specific radiation delivered in a condensed timeframe,” said Frank A. Vicini, M.D., radiation oncologist, 21st Century Oncology, Royal Oak, Mich. and contributing author to the 2009 and 2013 ASTRO and ABS APBI guidelines. “The results from this landmark, multicenter, prospective randomized clinical study are the first to offer the critical level one evidence necessary to drive the fundamental changes in breast conserving cancer treatment that patients and healthcare professionals have been demanding for years.”
To view the multimedia release go to:
http://www.multivu.com/players/uk/7661231-new-apbi-brachytherapy-data-at-astro-2015/
Researchers presenting at ASTRO 2015, the premier radiation oncology scientific event in the world, unveiled new data this week that could fundamentally change the way that early stage breast cancer is treated.
Results from a landmark prospective, randomized, multicenter phase III study conducted in Europe demonstrated that APBI brachytherapy leads to equivalent overall survival and local cancer control rates as compared to WBI after breast conserving surgery for selected patients with early stage breast cancers. These data were presented during the ASTRO official press conference and published in The Lancet, a leading high-impact global peer-reviewed medical journal.
“We have been confidently offering APBI brachytherapy to selected women for years based on numerous phase II, single site and large registry studies that have confirmed the clinical utility of site-specific radiation delivered in a condensed timeframe,” said Frank A. Vicini, M.D., radiation oncologist, 21st Century Oncology, Royal Oak, Mich. and contributing author to the 2009 and 2013 ASTRO and ABS APBI guidelines. “The results from this landmark, multicenter, prospective randomized clinical study are the first to offer the critical level one evidence necessary to drive the fundamental changes in breast conserving cancer treatment that patients and healthcare professionals have been demanding for years.”
To view the multimedia release go to:
http://www.multivu.com/players/uk/7661231-new-apbi-brachytherapy-data-at-astro-2015/
The Egyptian Ministry of Antiquities is pleased to announce the launch of an egyptian – international Project using non-invasive and non-destructive surveying techniques for the scanning of Egyptian Pyramids under the title “ScanPyramids” project.
Just because a mystery is 4500 years old doesn’t mean it can’t be solved…” This could be the motto of the exceptional scientific mission launched October 25, 2015, under the authority of the Egyptian Ministry of Antiquities, initiated, designed and coordinated by the Faculty of Engineering of Cairo and the French HIP.Institute (Heritage, Innovation and Preservation). Radiographic muons, aka cosmic particles, infrared thermography, photogrammetry, scanner and 3D reconstruction: the most innovative technologies will be used by researchers of international renown and three major universities: the Faculty of Engineering of Cairo University, Université Laval of Quebec and Nagoya University of Japan. Their goal: to probe the heart of the largest pyramids of Egypt, without drilling the slightest opening.
Four millennia after their construction, these ancient giants are far from having yielded their secrets. The first mystery concerns their construction, especially Khufu, the last of the Seven Wonders of the Ancient World still existing: it is still impossible to describe with certainty how this stone monument, the largest ever built by humans, was erected.
The “ScanPyramids” project has already been approved by the permanent committee of the Ministry of Antiquities and has obtained all necessary permissions from concerned authorities. With a base of more than 5 hectares, its original height of almost 150 meters and a mass of 5 million tons, how was it possible to construct such a wonder in only 25 years?
To view the multimedia release go to:
http://www.multivu.com/players/uk/7671551-scanpyramids-project-launch-egyptian/
Bestselling author Catherynne M. Valente (The Girl Who Circumnavigated Fairyland in a Ship of Her Own Making etc) returns to adult fiction with an eagerly awaited new novel: RADIANCE. She applies the phenomenal talent that made the Fairyland series so popular to give readers what she describes as a decopunk pulp science fiction alt-history space opera mystery set in a Hollywood—and solar system—very different from our own. http://www.catherynnemvalente.com YA, Fantasy, SciFi
